Top

BMC Public Health

Published in:

Open Access 01-12-2019 | Breast Cancer | Debate

Too much medicine? Scientific and ethical issues from a comparison between two conflicting paradigms

Author: Francesco Attena

Published in: BMC Public Health | Issue 1/2019

Abstract

Background

The role of medicine in society appears to be focused on two views, which may be summarized as follows: “Doing more means doing better” (paradigm A) and “Doing more does not mean doing better” (paradigm B).

Main body

I compared paradigms A and B both in terms of a single clinical condition and in the general context of a medical system. For a single clinical condition, I analyzed breast cancer screening. There are at least seven interconnected issues that influence the conflict between paradigms A and B in the debate on breast cancer screening: disconnection between research and practice; scarcity of information given to women; how “political correctness” can influence the choice of a health policy; professional interests; doubts about effectiveness; incommensurability between harms and benefits; and the difficulty in making dichotomous decisions with discrete variables. As a general approach to medicine, the main representative of paradigm A is systems medicine. As representatives of paradigm B, I identified the following approaches or movements: choosing wisely; watchful waiting; the Too Much Medicine campaign; slow medicine; complaints against overdiagnosis; and quaternary prevention. I showed that both as a single condition and as a general approach to medicine, the comparison was entirely reducible to a harm-benefit analysis; moreover, in both cases, the two paradigms are in many respects incommensurable. This transfers the debate to the ethical level; consequently, scientists and the public have equal rights and competence to debate on this subject. Moreover, systems medicine has many ethical problems that could limit its spread.

Conclusion

I made some hypotheses about scenarios for the future of medicine. I particularly focused on whether systems medicine would become increasingly accessible and widespread in the population or whether it would be downsized because its promises have not been maintained or ethical problems will become unsustainable.

Porter R. Blood and guts: a short history of medicine. London: Penguin; 2002.

Apweiler R, Beissbarth T, Berthold MR, Blüthgen N, Burmeister Y, Dammann O, et al. Whither systems medicine? Exp Mol Med. 2018;2:50(3):e453. https://doi.org/10.1038/emm.2017.290.

Jenniskens K, de Groot JAH, Reitsma JB, Moons KGM, Hooft L, Naaktgeboren CA. Overdiagnosis across medical disciplines: a scoping review. BMJ Open. 2017;7:e018448. https://doi.org/10.1136/bmjopen-2017-018448.CrossRefPubMedPubMedCentral

Kuhn T. The structure of scientific revolutions. Chicago: Chicago University Press; 1962.

Martin DK, Meslin EM, Kohut N, Singer PA. The incommensurability of research risks and benefits: practical help for research ethics committees. IRB. 1995;17:8–10.CrossRef

Waller J, Osborne K, Wardle J. Enthusiasm for cancer screening in Great Britain: a general population survey. Br J Cancer. 2015;112:562–6.CrossRef

Baena-Cañada JM, Rosado-Varela P, Expósito-Álvarez I, González-Guerrero M, Nieto-Vera J, Benítez-Rodríguez E. Women's perceptions of breast cancer screening. Spanish screening programme survey. Breast. 2014;23:883–8.CrossRef

Gigerenzer G, Mata J, Frank R. Public knowledge of benefits of breast and prostate cancer screening in Europe. J Natl Cancer Inst. 2009;101:1216–20.CrossRef

Wegwarth O, Gigerenzer G. The barrier to informed choice in cancer screening: statistical illiteracy in physicians and patients. Recent Results Cancer Res. 2018;210:207–21. https://doi.org/10.1007/978-3-319-64310-6_13.CrossRefPubMed

10.

Spagnoli L, Navaro M, Ferrara P, Del Prete V, Attena F. Collaborative Working Group. Online information about risks and benefits of screening mammography in 10 European countries: An observational Web sites analysis. Medicine (Baltimore). 2018;97:e10957. https://doi.org/10.1097/MD.0000000000010957.CrossRef

11.

Gøtzsche PC. Mammography screening: truth, lies and controversy. Boca Raton: CRC; 2012.

12.

Hofmann B. Fake facts and alternative truths in medical research. BMC Med Ethics. 2018;19:4. https://doi.org/10.1186/s12910-018-0243-z.CrossRefPubMedPubMedCentral

13.

Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013;108:2205–40. https://doi.org/10.1038/bjc.2013.177 Epub 2013 Jun 6.CrossRefPubMedPubMedCentral

14.

Njor S, Nyström L, Moss S, Paci E, Broeders M, Segnan N, Lynge E. Euroscreen Working Group. Breast cancer mortality in mammographic screening in Europe: a review of incidence-based mortality studies. J Med Screen. 2012;19(Suppl 1):33–41.CrossRef

15.

Weedon-Fekjær H, Romundstad PR, VattEn LJ. Modern mammography screening and breast cancer mortality: population study. BMJ. 2014 Jun 17;348:g3701. https://doi.org/10.1136/bmj.g3701.CrossRefPubMedPubMedCentral

16.

Siu AL; U.S. Preventive Services Task Force. Screening for breast cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016;164:279–296. https://doi.org/10.7326/M15-2886. Epub 2016 Jan 12.

17.

Puliti D, Bucchi L, Mancini S, Paci E, Baracco S, Campari C, Canuti D, Cirilli C, Collina N, Conti GM, Di Felice E, Falcini F, Michiara M, Negri R, Ravaioli A, Sassoli De’ Bianchi P, Serafini M, Zorzi M, Caldarella A, Cataliotti L, Zappa M. IMPACT COHORT Working Group. Advanced breast cancer rates in the epoch of service screening: The 400,000 women cohort study from Italy. Eur J Cancer. 2017;75:109–16. https://doi.org/10.1016/j.ejca.2016.12.030 Epub 2017 Feb 20.CrossRefPubMed

18.

Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA. 2009;302:1685–92. https://doi.org/10.1001/jama.2009.1498.CrossRefPubMed

19.

Mukhtar TK, Yeates DR, Goldacre MJ. Breast cancer mortality trends in England and the assessment of the effectiveness of mammography screening: population-based study. J R Soc Med. 2013;106:234–42. https://doi.org/10.1177/0141076813486779.CrossRefPubMedPubMedCentral

20.

Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013;Jun 4:CD001877. https://doi.org/10.1002/14651858.CD001877.

21.

Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348:g366. https://doi.org/10.1136/bmj.g366.CrossRefPubMedPubMedCentral

22.

Autier P, Boniol M. Mammography screening: a major issue in medicine. Eur J Cancer. 2018;90:34–62. https://doi.org/10.1016/j.ejca.2017.11.002 Epub 2017 Dec 20.CrossRefPubMed

23.

Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S, et al. Benefits and harms of breast cancer screening: a systematic review. JAMA. 2015;314:1615–34. https://doi.org/10.1001/jama.2015.13183.CrossRefPubMed

24.

Paci E, Broeders M, Hofvind S, Puliti D. Duffy SW; EUROSCREEN working group. European breast cancer service screening outcomes: a first balance sheet of the benefits and harms. Cancer Epidemiol Biomark Prev. 2014;23:1159–63. https://doi.org/10.1158/1055-9965.EPI-13-0320.CrossRef

25.

Hofvind S, Román M, Sebuødegård S, Falk RS. Balancing the benefits and detriments among women targeted by the Norwegian breast Cancer screening program. J Med Screen. 2016;23:203–9 Epub 2016 Mar 2.CrossRef

26.

Løberg M, Lousdal ML, Bretthauer M, Kalager M. Benefits and harms of mammography screening. Breast Cancer Res. 2015;17:63. https://doi.org/10.1186/s13058-015-0525-z.CrossRefPubMedPubMedCentral

27.

Keating NL, Pace LE. Breast cancer screening in 2018: time for shared decision making. JAMA. 2018;319:1814–5. https://doi.org/10.1001/jama.2018.3388.CrossRefPubMed

28.

Tonelli M, Connor Gorber S, Joffres M, Dickinson J, Singh H, Lewin G, et al. Recommendations on screening for breast cancer in average-risk women aged 40-74 years. Canadian task force on preventive health care. CMAJ. 2011;183:1991–2001. https://doi.org/10.1503/cmaj.110334.CrossRefPubMed

29.

Njor SH, Paci E, Rebolj M. As you like it: how the same data can support manifold views of overdiagnosis in breast cancer screening. Int J Cancer. 2018 Apr 6. https://doi.org/10.1002/ijc.31420 [Epub ahead of print].

30.

Hendrick RE. Obligate overdiagnosis due to mammographic screening: a direct estimate for U.S. women. Radiology 2018;287(2):391–397. https://doi.org/10.1148/radiol.2017171622. Epub 2017 Dec 21.

31.

Johansson M, Jørgensen KJ, Getz L, Moynihan R. "informed choice" in a time of too much medicine-no panacea for ethical difficulties. BMJ. 2016 May 9;353:i2230. https://doi.org/10.1136/bmj.i2230.CrossRefPubMed

32.

Onega T, Beaber EF, Sprague BL, Barlow WE, Haas JS, Tosteson AN, et al. Breast cancer screening in an era of personalized regimens: a conceptual model and National Cancer Institute initiative for risk-based and preference-based approaches at a population level. Cancer. 2014;120(19):2955–64. https://doi.org/10.1002/cncr.28771 Epub 2014 May 15.CrossRefPubMedPubMedCentral

33.

Doria-Rose, V.P., Marcus P., Klabunde, C., Ballard-Barbash, R., Pressman, E., Rozjabek, H., et al. The PROSPR Initiative: Competitive Revision for the Collection of Cervical Cancer Screening Process Data by Two Existing PROSPR Research Centers. https://deainfo.nci.nih.gov/advisory/joint/0613/DoriaRose.pdf. Accessed 6 Jun 2018.

34.

Ayers D, Day PJ. Systems medicine: the application of systems biology approaches for modern medical research and drug development. Mol Biol Int. 2015;2015:698169. https://doi.org/10.1155/2015/698169 Epub 2015 Aug 18.CrossRefPubMedPubMedCentral

35.

Ideker T, Galitski T, Hood L. A new approach to decoding life: systems biology. Annu Rev Genomics Hum Genet. 2001;2:343–72.CrossRef

36.

Hood L, Flores M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. New Biotechnol. 2012;29:613–24. https://doi.org/10.1016/j.nbt.2012.03.004 Epub 2012 Mar 18.CrossRef

37.

Institute for Systems Biology. https://www.systemsbiology.org. Accessed 7 Jun 2018.

38.

European Institute for Systems Biology and Medicine. http://www.eisbm.org. Accessed 7 Jun 2018.

39.

Suzhou Institute of Systems Medicine. http://www.ismsz.cn/Index/EDefault. Accessed 7 Jun 2018.

40.

Choosing Wisely. http://www.choosingwisely.org. Accessed 13 Jun 2018.

41.

Levinson W, Kallewaard M, Bhatia RS, Wolfson D, Shortt S, Kerr EA. Choosing Wisely International Working Group. ‘Choosing Wisely’: a growing international campaign. BMJ Qual Saf. 2015;24:167–74. https://doi.org/10.1136/bmjqs-2014-003821 Epub 2014 Dec 31.CrossRefPubMed

42.

Rittenmeyer L, Huffman D, Alagna M, Moore E. The experience of adults who choose watchful waiting or active surveillance as an approach to medical treatment: a qualitative systematic review. JBI Database System Rev Implement Rep. 2016;14:174–255. https://doi.org/10.11124/jbisrir-2016-2270.CrossRefPubMed

43.

Chodak GW. The role of watchful waiting in the management of localized prostate cancer. J Urol. 1994;152(5 Pt 2):1766–8.CrossRef

44.

NCI Dictionary of Cancer Terms. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/watchful-waiting. Accessed 13 Jun 2018.

45.

Moynihan R. Too much medicine? The business of health — and its risks for you. Sydney: ABC Books; 1998.

46.

Too Much Medicine. https://www.bmj.com/too-much-medicine. Accessed 13 Jun 2018.

47.

Bonaldi A, Vernero S. Slow medicine: un nuovo paradigma in medicina [Italy's slow medicine: a new paradigm in medicine]. Recenti Prog Med. 2015;106:85–91. https://doi.org/10.1701/1790.19492.CrossRefPubMed

48.

Slow Medicine. https://www.slowmedicine.it/index.php/it. Accessed 13 Jun 2018.

49.

Welch HG, Schwartz L, Woloshin S. Overdiagnosed: making people sick in the pursuit of health. Boston: Beacon Press; 2011.

50.

Pathirana T, Clark J, Moynihan R. Mapping the drivers of overdiagnosis to potential solutions. BMJ. 2017;358:j3879. https://doi.org/10.1136/bmj.j3879.CrossRefPubMed

51.

Martins C, Godycki-Cwirko M, Heleno B, Brodersen J. Quaternary prevention: reviewing the concept. Eur J Gen Pract. 2018;24:106–11. https://doi.org/10.1080/13814788.2017.1422177.CrossRefPubMedPubMedCentral

52.

Bentzen N. WONCA dictionary of general/family practice. Copenhagen: Laegeforeningens Forlag; 2003.

53.

Vandamme D, Fitzmaurice W, Kholodenko B, Kolch W. Systems medicine: helping us understand the complexity of disease. QJM. 2013;106:891–5. https://doi.org/10.1093/qjmed/hct163 Epub 2013 Jul 30.CrossRefPubMed

54.

Laplace PS. A philosophical essay on probabilities, translated into English from the original French. Truscott FW, Emory FL, editors. New York: John Wiley & Sons; 1902.

55.

Hood L, Balling R, Auffray C. Revolutionizing medicine in the 21st century through systems approaches. Biotechnol J. 2012;7:992–1001. https://doi.org/10.1002/biot.201100306 Epub 2012 Jul 20.CrossRefPubMedPubMedCentral

56.

Vogt H, Hofmann B, Getz L. The new holism: P4 systems medicine and the medicalization of health and life itself. Med Health Care Philos. 2016;19:307–23. https://doi.org/10.1007/s11019-016-9683-8.CrossRefPubMedPubMedCentral

57.

Asmundson GJ, Abramowitz JS, Richter AA, Whedon M. Health anxiety: current perspectives and future directions. Curr Psychiatry Rep. 2010;12:306–12. https://doi.org/10.1007/s11920-010-0123-9.CrossRefPubMed

58.

Muse K, McManus F, Leung C, Meghreblian B, Williams JM. Cyberchondriasis: fact or fiction? A preliminary examination of the relationship between health anxiety and searching for health information on the internet. J Anxiety Disord. 2012;26:189–96. https://doi.org/10.1016/j.janxdis.2011.11.005 Epub 2011 Nov 15.CrossRefPubMed

59.

Salerno J, Knoppers BM, Lee LM, Hlaing WM, Goodman KW. Ethics, big data and computing in epidemiology and public health. Ann Epidemiol. 2017;27:297–301. https://doi.org/10.1016/j.annepidem.2017.05.002 Epub 2017 May 10.CrossRefPubMed

60.

Mittelstadt BD, Floridi L. The ethics of big data: current and foreseeable issues in biomedical contexts. Sci Eng Ethics. 2016;22:303–41. https://doi.org/10.1007/s11948-015-9652-2 Epub 2015 May 23.CrossRefPubMed

61.

Fischer T, Brothers KB, Erdmann P, Langanke M. Clinical decision-making and secondary findings in systems medicine. BMC Med Ethics. 2016;17:32. https://doi.org/10.1186/s12910-016-0113-5.CrossRefPubMedPubMedCentral

62.

Hood L. Systems biology and P4 medicine: Past, present, and future. Rambam Maimonides Med J. 2013; 4(2): e0012. Published online 2013 Apr 30. https://doi.org/10.5041/RMMJ.1011

Title: Too much medicine? Scientific and ethical issues from a comparison between two conflicting paradigms
Author: Francesco Attena
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Published in: BMC Public Health / Issue 1/2019
Electronic ISSN: 1471-2458
DOI: https://doi.org/10.1186/s12889-019-6442-9

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Too much medicine? Scientific and ethical issues from a comparison between two conflicting paradigms

Abstract

Background

Main body

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Main body

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

Dental care utilization: examining the associations between health services deficits and not having a dental visit in past 12 months

Exploring HIV concern in a population of Dominican American women midlife and older

Factors related to out-of-hours help-seeking for acute health problems: a survey study using case scenarios

SKIP (Supporting Kids with diabetes In Physical activity): Feasibility of a randomised controlled trial of a digital intervention for 9-12 year olds with type 1 diabetes mellitus

Overall gestational weight gain mediates the relationship between maternal and child obesity

Patients’ experiences of physical activity on prescription with access to counsellors in routine care: a qualitative study in Sweden